JPRN-UMIN000038065
Recruiting
未知
An observational study to evaluate the impact of the gene panel test FoundationOne CDx or FoundationOne Liquid CDx on treatment decision-making in metastatic and recurrent breast cancer throughout Japan as a whole. - JBCRG-C07(REIWA Study)
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Patients with stage IV or recurrent breast cancer who have distant metastases at registration
- Sponsor
- Japan Breast Cancer Research Group
- Enrollment
- 600
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients with active invasive double cancer within 5 years or patients with active invasive double cancer that currently needs treatment.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Effect of Apatarpankar Hetus on Krusha Pramehi (low BMI Diabetic patients) and their Blood Sugar LevelCTRI/2018/11/016321PDEAs College of Ayurved and Research Center
Not yet recruiting
Not Applicable
Effects of commonly used anti-anxiety drugs on patientsCTRI/2023/01/048752Dr Dnyaneshwar Kurle
Not yet recruiting
Not Applicable
An Observational study to evaluate the impact of Ayurvedic management in Amavata (Rheumatoid Arthritis ) previously treated with allopathic medicine.Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecifiedCTRI/2024/05/067683State Ayurvedic College and Hospital Lucknow
Recruiting
Not Applicable
Growth of skin cancers around the eye – the impact of waiting time for elective surgery.Growth rate of basal cell carcinomas (a type of skin cancer) around the eye whilst patients await elective surgery.Skin - Other skin conditionsCancer - Non melanoma skin cancerACTRN12610000542099Stephen Ng200
Completed
Not Applicable
Observational Study to Assess the Effect of the Accu-Chek® SugarView app on Subjects withType 2 DiabetesHealth Condition 1: E119- Type 2 diabetes mellitus without complicationsCTRI/2022/06/043130Roche Diabetes Care India Pvt Ltd100